Related Experiment Video
Updated: May 19, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Alzheimer's disease diagnostic criteria: practical applications
1Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W. Bonneville Avenue, Las Vegas, NV 89106, USA.
Alzheimer'S Research & Therapy
|September 6, 2012
Summary
Biomarkers enable early Alzheimer's disease (AD) identification before dementia. New criteria define three AD phases, impacting diagnosis and patient awareness.
Area of Science:
- Neurology
- Biomarker research
- Neurodegenerative diseases
Background:
- Alzheimer's disease (AD) diagnosis traditionally relies on dementia symptoms.
- Biomarkers offer potential for identifying AD in pre-dementia stages.
- Previous criteria (2007, 2010) established early AD phases.
Purpose of the Study:
- To compare and contrast the International Work Group (IWG) and National Institute on Aging/Alzheimer's Association (NIA/AA) criteria for Alzheimer's disease phases.
- To highlight similarities and differences in diagnostic approaches and biomarker integration.
- To discuss the implications of revised AD diagnostic criteria.
Main Methods:
- Comparative analysis of IWG and NIA/AA criteria for Alzheimer's disease staging.
- Review of diagnostic frameworks and biomarker requirements for each set of criteria.
- Examination of the clinical and practical implications of these diagnostic approaches.
Main Results:
- Both IWG and NIA/AA criteria recognize AD onset before dementia, defining three similar phases (asymptomatic biomarker-positive, mild cognitive impairment, dementia).
- IWG criteria propose a unified clinico-biological approach, integrating biomarkers across all symptomatic phases.
- NIA/AA criteria utilize distinct diagnostic approaches for each phase, with optional biomarker integration.
Conclusions:
- Current AD criteria, while advanced, have limitations requiring future revisions.
- The adoption of these criteria significantly expands the number of individuals identified with AD.
- Patients will have earlier knowledge of their AD diagnosis, impacting disease management and personal planning.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.